<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842267</url>
  </required_header>
  <id_info>
    <org_study_id>LG-DPCL019</org_study_id>
    <nct_id>NCT03842267</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of Gemigliptin 50mg in Patients With Type 2 Diabetes Who Have Inadequate glycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg&#xD;
      orally administered once daily for 24 weeks compared with placebo in patients with type 2&#xD;
      diabetes mellitus who have inadequate glycemic control with dapagliflozin and metformin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Actual">May 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline HbA1c at week 24</measure>
    <time_frame>Baseline (week 0) and week 24</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Gemigliptin 50mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemigliptin Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin 50mg</intervention_name>
    <description>The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.&#xD;
Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:&#xD;
Dapagliflozin 10 mg / day&#xD;
Metformin ≥ 1,000 mg / day</description>
    <arm_group_label>Gemigliptin 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin Placebo</intervention_name>
    <description>The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.&#xD;
- The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.&#xD;
Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:&#xD;
Dapagliflozin 10 mg / day&#xD;
Metformin ≥ 1,000 mg / day</description>
    <arm_group_label>Gemigliptin Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with type 2 diabetes mellitus of upper 19 years old at the time of Visit 1&#xD;
             (Screening)&#xD;
&#xD;
          2. Visit 1 (Screening) Patients who had taken Dapagliflozin 10mg/day and&#xD;
             Metformin(≥1000mg/day) more than 8 weeks and who have inadequate blood glucose control&#xD;
             at Visit 1 (Screening)&#xD;
&#xD;
          3. Patients who have signed an informed consent themselves after receiving explanation&#xD;
             about the objectives, methods, effects, etc. of the clinical study&#xD;
&#xD;
          4. Patients who are applicable to one of the three in the following. 1) Surgically&#xD;
             infertile patients 2) Postmenopausal female patients of ≥45 years of age for whom ≥2&#xD;
             years elapsed since their last menstruation 3) Premenopausal fertile female patients&#xD;
             or surgically non-infertile male patients who have agreed to use at least 2 kinds of&#xD;
             contraceptive measures (certainly including one of the barrier methods) to avoid&#xD;
             pregnancy until 14 days after the last dose of the investigational product&#xD;
&#xD;
               -  Barrier methods: Condom, Diaphragm, Cervical cap(Pessary), Spermicide&#xD;
&#xD;
               -  Hormonal methods: Pills, Injection(Depot), Skin patch, Hormonal&#xD;
                  implant(Implanon), Vaginal ring&#xD;
&#xD;
               -  Intrauterine Devices(IUDs): Cooper IUD(Loop), Hormonal IUD(Mirena)&#xD;
&#xD;
               -  Natural methods: Basic body temperature, Ovulation period, Coitus interruptus,&#xD;
                  Abstinence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with type 1 diabetes mellitus, Diabetic ketoacidosis, Metabolic acidosis&#xD;
             Diabetic coma, Diabetic pre-coma&#xD;
&#xD;
          2. Patients with Gestational diabetes, or secondary diabetes&#xD;
&#xD;
          3. Patients with Body Mass Index(BMI) &gt;40 kg/m2 at the time of Visit 1(Screening)&#xD;
&#xD;
          4. Patients with a history of the following&#xD;
&#xD;
               -  Patients with NYHA Class II~IV congestive heart failure or arrhythmia requiring&#xD;
                  treatment at the time of Visit 1(Screening)&#xD;
&#xD;
               -  Patients whose TSH level is out of the normal range and who have thyroidal&#xD;
                  dysfunction requiring drug therapy at the time of Visit 1(Screening) (However,&#xD;
                  those who have been taking thyroid hormone at a fixed dose since previous 4 weeks&#xD;
                  prior to Visit 1(Screening) and whose TSH level is within the normal range can&#xD;
                  participate in the study.)&#xD;
&#xD;
               -  Patients with a glomerular filtration rate (eGFR) less than 45 mL/min /1.73 m2,&#xD;
                  moderate of severe stage renal disease, end-stage renal disease, dialysis at the&#xD;
                  time of Visit 1(Screening)&#xD;
&#xD;
               -  Patients who are receiving intravenous iodine contrast agents within 48 hours&#xD;
                  prior to Visit 1(Screening) or planned during the clinical trial period (eg,&#xD;
                  intravenous urography, venous cholangiography, angiography, computed tomography&#xD;
                  using contrast media, etc.).&#xD;
&#xD;
               -  Patients with pulmonary embolism, severe pulmonary dysfunction, or who are&#xD;
                  susceptible to be accompanied by hypoxemia at the time of Visit 1(Screening)&#xD;
&#xD;
               -  Patients on dehydration, diarrhea, and vomiting at the time of Visit 1(Screening)&#xD;
&#xD;
               -  Patients with pituitary insufficiency or adrenal insufficiency at the time of&#xD;
                  Visit 1(Screening)&#xD;
&#xD;
               -  Patients with a history of myocardial infarction, unstable angina, and&#xD;
                  Cerebrovascular disease within 12 weeks prior to Visit 1(Screening)&#xD;
&#xD;
               -  Patients who had had a surgical operation within 4 weeks prior to Visit&#xD;
                  1(Screening) (excluding minor surgeries without restriction on food and fluid&#xD;
                  intake) or who are scheduled to have a significant surgery during the study&#xD;
                  period&#xD;
&#xD;
               -  Patients with a history of alcoholism or drug addiction within 1 years prior to&#xD;
                  Visit 1(Screening)&#xD;
&#xD;
               -  Patients with a history of malignant tumors within 5 years prior to Visit&#xD;
                  1(Screening). However, patients with basal cell or squamous cell skin cancer, or&#xD;
                  in situ cervical cancer treated properly can participate in the study.&#xD;
&#xD;
          5. Patients with the outcomes of the laboratory tests performed at Visit 1(Screening)&#xD;
             applicable to the criteria below&#xD;
&#xD;
               -  Bilirubin &gt;2 × upper limit of normal(ULN)&#xD;
&#xD;
               -  AST/ALT &gt;3 × ULN&#xD;
&#xD;
          6. Patients with a history of hypersensitivity reactions to the drugs below&#xD;
&#xD;
               -  Dipeptidyl-peptidase4(DPP4) inhibitors&#xD;
&#xD;
               -  Sodium/glucose co transport-2(SGLT-2) inhibitor&#xD;
&#xD;
               -  Biguanides&#xD;
&#xD;
          7. Patients who were administered the drugs below&#xD;
&#xD;
               -  Patients who had been administered anti-obesity drugs within 12 weeks prior to&#xD;
                  Visit 1(Screening)&#xD;
&#xD;
               -  Patients who had been administered insulin or GLP-1 analogues within 8 weeks&#xD;
                  prior to Visit 1(Screening)&#xD;
&#xD;
               -  Patients who had been being administered glucocorticoids, Strong CYP3A4 inducers&#xD;
                  continuously within 2 weeks prior to Visit 1(Screening) or who are required to&#xD;
                  take glucocorticoids continuously in the future&#xD;
&#xD;
          8. Patients with positive Serologic results of HBsAg, HCV Ab, HIV Ab test within 4 weeks&#xD;
             prior to Visit 1 (Screening) or at Visit 1 (Screening)&#xD;
&#xD;
          9. Patients who have undergone bariatric surgery within the 1 year prior to Visit 1&#xD;
             (Screening) or are scheduled during the trial&#xD;
&#xD;
         10. Patients with a genetic problems such as Galactose intolerance, Lapp lactose&#xD;
             deficiency, Glucose-galactose malabsorption)&#xD;
&#xD;
         11. Female patients who are pregnant or lactating&#xD;
&#xD;
         12. Patients who have an experience of participation in another clinical study within 12&#xD;
             weeks prior to Visit1(screening)&#xD;
&#xD;
         13. Patients who are otherwise considered to be ineligible for this study on&#xD;
             investigators' judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LG chem</name>
      <address>
        <city>Seoul</city>
        <state>Gangseo-Gu</state>
        <zip>07795</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

